Novo Nordisk reported sales of DKK 154.944 billion in the first six months of this year, a 16% year-on-year increase, and net profit of DKK 55.537 billion. Among its star products, semaglutide generated sales of DKK 112.756 billion in the first half of the year. Of this, sales of the glucose-lowering semaglutide injection (Ozempic) reached DKK 64.52 billion, while sales of the weight-loss semaglutide injection (Wegovy) reached DKK 36.888 billion. Converted into US dollars, semaglutide sales reached $17.5 billion in the first half of this year. This means that semaglutide surpassed the top-selling drug, pembrolizumab, also known as "K drug," during the period.